Étiquette : microdosing

Powerful substances in tiny amounts: Exploring the practice of microdosing psychedelic drugs, Petter Grahl Johnstad, 2017

Powerful substances in tiny amounts: Exploring the practice of microdosing psychedelic drugs Petter Grahl Johnstad, Pré-Print, 2017.   This article presents an explorative study of microdosing practices with psychedelic drugs. A microdose is defined as a sub-perceptual dose, commonly about one tenth of an ordinary recreational dose, which gives no alteration of consciousness or feeling of intoxication. Respondents (n = 17) were recruited at several Internet fora for individual interviews mediated via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job and relationship and extensive entheogen experience. Respondents tended to experiment with microdosing in phases, [...]

Lire la suite

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, L.S. Kaertner et al., 2021

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing, KAERTNER L.S., STEINBORN M.B., KETTNER H., SPRIGGS M.J., ROSEMAN L., BUCHBORN T., BALAET M., TIMMERMANN C., ERRITZOE D., CARHARDT-HARRIS R.L. : Nature, 2021, 11, 1941 Doi : 1038/s41598-021-81446-7   Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic [...]

Lire la suite

Psychedelics as a Treatment for Alzheimer’s Disease Dementia, Simon Andrew Vann Jones and Allison O’Kelly, 2020

Psychedelics as a Treatment for Alzheimer’s Disease Dementia Simon Andrew Vann Jones and Allison O’Kelly Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34 doi : 10.3389/fnsyn.2020.00034   Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic [...]

Lire la suite

Microdosing psychedelics : Motivations, subjective effects and harm reduction, Toby Lea et al., 2020

Microdosing psychedelics : Motivations, subjective effects and harm reduction Toby Lea, Nicole Amada, Henrik Jungaberl, Henrike Schecke, Michael Klein International Journal of Drug Policy, 2020, 75, 102600, 9 p. Doi : 10.1016/j.drugpo.2019.11.008 A B S T R A C T Background : In recent years there has been growing media attention on microdosing psychedelics (e.g., LSD, psilocybin). This refers to people routinely taking small doses of psychedelic substances to improve mental health and wellbeing, or to enhance cognitive performance. Research evidence is currently limited. This paper examines microdosing motivations, dosing practices, perceived short-term benefits, unwanted effects, and harm reduction practices. Methods : An international online survey [...]

Lire la suite

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders, Toby Lea et al., 2020

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders Toby Lea & Nicole Amada & Henrik Jungaberle & Henrike Schecke & Norbert Scherbaum & Michael Klein Psychopharmacology, 2020. Di : 10.1007/s00213-020-05477-0   Abstract Rationale : The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. Objectives : This paper examined subjective experiences of microdosing psychedelics to improve mental health or to cease [...]

Lire la suite

Microdosing psychedelics : Demographics, practices, and psychiatric comorbidities, Daniel Rosenbaum, et al., 2020

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities Daniel Rosenbaum, Cory Weissman, Thomas Anderson, Rotem Petranker, Le-Anh Dinh-Williams, Katrina Hui and Emma Hapke Journal of Psychopharmacology, 2020, 1-11. doi.org/10.1177/0269881120908004   Abstract Rationale : Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives : To examine the practices and demographics of a population of psychedelic microdosers – including their psychiatric diagnoses, prescription medications, and recreational substance use patterns – to develop a foundation [...]

Lire la suite

LSD : microdoses festives, Céline Zünd, Le Temps, mardi 28 janvier 2020

LSD : microdoses festives Céline ZÜND Le Temps, mardi 28 janvier 2020 https://www.letemps.ch/societe/lsd-microdoses-festives?utm_campaign=article_traffic&utm_content=1580242382&utm_medium=social&utm_source=facebook&fbclid=IwAR3v1uDm_lCzk_Bb1XMeRzSxcxr-mHObGhhPeJVK-Fa0y6rczvc3DFJ3H78   La prise de LSD en petites quantités fait toujours plus d'adeptes, dans les milieux festifs, au travail ou en automédication. Or la recherche scientifique ne dispose pas de données fiables sur les véritables effets de cette substance, ni sur ses risques potentiels. Ursina s’est longtemps refusée à la tentation d’accompagner ses nuits festives de substances chimiques. «J’avais peur du mauvais trip», dit la Zurichoise de 40 ans, casquette et bomber satiné. Jusqu’à ce qu’elle entende parler du LSD en microdose. Elle se procure l’hallucinogène une première fois il y [...]

Lire la suite

Psychedelics and potential benefits in “healthy normals”: A review of the literature, Sam GANDY, 2019

Psychedelics and potential benefits in “healthy normals”: A review of the literature Sam GANDY Journal of Psychedelic Studies, 2019, 3, (3), 280–287. Doi : 10.1556/2054.2019.029   We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of mental health indications still in its early stages, there is an increasing body of research to show that careful use of psychedelics can yield a variety of benefits in “healthy normals” and so lead to “the betterment of well people.” Psychedelics have been found to modulate neuroplasticity, and usage in a supportive setting can result [...]

Lire la suite

The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial, Steliana Yanakieva et al., 2018

The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial Steliana Yanakieva, Naya Polychroni, Neiloufar Family, Luke T. J. Williams, David P. Luke, Devin B. Terhune Psychopharmacology, 2018 Doi : 10.1007/s00213-018-5119-x   Abstract Rationale : Previous research demonstrating that lysergic acid diethylamide (LSD) produces alterations in time perception has implications for its impact on conscious states and a range of psychological functions that necessitate precise interval timing. However, interpretation of this research is hindered by methodological limitations and an inability to dissociate direct neurochemical effects on interval timing from indirect effects attributable to altered states of consciousness. Methods : We conducted a randomised, double-blind, [...]

Lire la suite